{"id":"NCT00414973","sponsor":"Eli Lilly and Company","briefTitle":"A Study for Patients With Osteoporosis","officialTitle":"Comparison of Teriparatide and Calcitonin in the Treatment of Men and Postmenopausal Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2006-12-22","resultsPosted":"2009-08-26","lastUpdate":"2009-10-28"},"enrollment":364,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Teriparatide","otherNames":["LY333334","Forteo","Forsteo"]},{"type":"DRUG","name":"Salmon Calcitonin","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis","primaryOutcome":{"measure":"Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women","timeFrame":"Baseline to 24 weeks","effectByArm":[{"arm":"Teriparatide - Females","deltaMin":6.04,"sd":0.48},{"arm":"Calcitonin - Females","deltaMin":1.65,"sd":0.65}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":5,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Dizziness","Muscle spasms","Pain in extremity","Nasopharyngitis","Blood alkaline phosphatase increased"]}}